CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving lung cancer treatment by identifying specific genetic and epigenetic markers that can serve as targets for new therapies. It aims to develop a predictive model for treatment responses, enhancing personalized medicine approaches for lung and other epithelial cancers.
Lung cancer (LC) is still the most lethal type of cancer worldwide.
The extremely poor prognosis for LC patients is partly due to the lack of effective therapies.
At present, most patients with pulmonary carcinomas are treated with chemotherapy.
This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases.
In spite of the rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving…
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Liverpool
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, GRENOBLE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
